Gut microbiome structure and metabolic activity in inflammatory bowel disease

被引:0
|
作者
Eric A. Franzosa
Alexandra Sirota-Madi
Julian Avila-Pacheco
Nadine Fornelos
Henry J. Haiser
Stefan Reinker
Tommi Vatanen
A. Brantley Hall
Himel Mallick
Lauren J. McIver
Jenny S. Sauk
Robin G. Wilson
Betsy W. Stevens
Justin M. Scott
Kerry Pierce
Amy A. Deik
Kevin Bullock
Floris Imhann
Jeffrey A. Porter
Alexandra Zhernakova
Jingyuan Fu
Rinse K. Weersma
Cisca Wijmenga
Clary B. Clish
Hera Vlamakis
Curtis Huttenhower
Ramnik J. Xavier
机构
[1] Broad Institute of MIT and Harvard,Department of Biostatistics
[2] Harvard School of Public Health,Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease
[3] Novartis Institute for Biomedical Research Inc.,Department of Immunology, K.G. Jebsen Coeliac Disease Research Centre
[4] Massachusetts General Hospital and Harvard Medical School,Center for Microbiome Informatics and Therapeutics
[5] Department of Gastroenterology and Hepatology,undefined
[6] University of Groningen and University Medical Center Groningen,undefined
[7] Department of Genetics,undefined
[8] University of Groningen and University Medical Center Groningen,undefined
[9] Novartis Institute for Biomedical Research Inc.,undefined
[10] Department of Pediatrics,undefined
[11] University of Groningen and University Medical Center Groningen,undefined
[12] University of Oslo,undefined
[13] Massachusetts Institute of Technology,undefined
来源
Nature Microbiology | 2019年 / 4卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The inflammatory bowel diseases (IBDs), which include Crohn’s disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastrointestinal tract. While IBD has been associated with dramatic changes in the gut microbiota, changes in the gut metabolome—the molecular interface between host and microbiota—are less well understood. To address this gap, we performed untargeted metabolomic and shotgun metagenomic profiling of cross-sectional stool samples from discovery (n = 155) and validation (n = 65) cohorts of CD, UC and non-IBD control patients. Metabolomic and metagenomic profiles were broadly correlated with faecal calprotectin levels (a measure of gut inflammation). Across >8,000 measured metabolite features, we identified chemicals and chemical classes that were differentially abundant in IBD, including enrichments for sphingolipids and bile acids, and depletions for triacylglycerols and tetrapyrroles. While > 50% of differentially abundant metabolite features were uncharacterized, many could be assigned putative roles through metabolomic ‘guilt by association’ (covariation with known metabolites). Differentially abundant species and functions from the metagenomic profiles reflected adaptation to oxidative stress in the IBD gut, and were individually consistent with previous findings. Integrating these data, however, we identified 122 robust associations between differentially abundant species and well-characterized differentially abundant metabolites, indicating possible mechanistic relationships that are perturbed in IBD. Finally, we found that metabolome- and metagenome-based classifiers of IBD status were highly accurate and, like the vast majority of individual trends, generalized well to the independent validation cohort. Our findings thus provide an improved understanding of perturbations of the microbiome–metabolome interface in IBD, including identification of many potential diagnostic and therapeutic targets.
引用
收藏
页码:293 / 305
页数:12
相关论文
共 50 条
  • [21] Gut microbiome in inflammatory bowel disease patients with and without arthropathy
    Kabeerdoss, J.
    Pugazhendhi, S.
    Balekuderu, A.
    Prabavathi, D.
    Goel, R.
    Danda, D.
    Ramakrishna, B. S.
    FEBS JOURNAL, 2014, 281 : 661 - 661
  • [22] Interactions between Medications and the Gut Microbiome in Inflammatory Bowel Disease
    Eckenberger, Julia
    Butler, James C.
    Bernstein, Charles N.
    Shanahan, Fergus
    Claesson, Marcus J.
    MICROORGANISMS, 2022, 10 (10)
  • [23] Metabolic network of the gut microbiota in inflammatory bowel disease
    Sugihara, Kohei
    Kamada, Nobuhiko
    INFLAMMATION AND REGENERATION, 2024, 44 (01)
  • [24] The Gut Microbiome and Inflammatory Bowel Diseases
    Shan, Yue
    Lee, Mirae
    Chang, Eugene B.
    ANNUAL REVIEW OF MEDICINE, 2022, 73 : 455 - 468
  • [25] Metabolic network of the gut microbiota in inflammatory bowel disease
    Kohei Sugihara
    Nobuhiko Kamada
    Inflammation and Regeneration, 44
  • [26] Metabolic Phenotypes as Potential Biomarkers for Linking Gut Microbiome With Inflammatory Bowel Diseases
    Iablokov, Stanislav N.
    Klimenko, Natalia S.
    Efimova, Daria A.
    Shashkova, Tatiana
    Novichkov, Pavel S.
    Rodionov, Dmitry A.
    Tyakht, Alexander V.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 7
  • [27] Inflammatory Bowel Disease and Cardiovascular Disease: An Integrative Review With a Focus on the Gut Microbiome
    Cruz, Camila Sanchez
    Huerta, Anahi Rojas
    Barrientos, Jesus Lima
    Rodriguez, Cristina
    Devani, Aarfa
    Boosahda, Vanessa
    Mareddy, Naga S. Rasagna
    Silva, Gabriela Briceno
    Miranda, Jose C. Del Castillo
    Gochi, Kevin A. Reyes
    Gochi, Mario D. Reyes
    Alvarez, Samantha
    Hasbun, Patricia E. Ghattas
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [28] The Role of the Human Gut Microbiome in Inflammatory Bowel Disease and Radiation Enteropathy
    Fernandes, Darren
    Andreyev, Jervoise
    MICROORGANISMS, 2022, 10 (08)
  • [29] Inflammatory bowel disease biomarkers revealed by the human gut microbiome network
    Hu, Mirko
    Caldarelli, Guido
    Gili, Tommaso
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [30] The Role of the Gut Microbiome in Inflammatory Bowel Disease: The Middle East Perspective
    El-Sayed, Ahmed
    Kapila, Diya
    Taha, Rama Sami Issa
    El-Sayed, Sherif
    Mahen, Mohd Rafiw Ahmed
    Taha, Roa'a
    Alrubaiy, Laith
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (06):